Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study-Reference-Cited by-同舟云学术

Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study

Published:2020-05 Issue:5 Volume:10 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Mina Roberto^ORCID,Belotti Angelo,Petrucci Maria Teresa,Zambello Renato,Capra Andrea,Di Lullo Giacomo,Ronconi Sonia,Pescosta Norbert,Grasso Mariella,Monaco Federico,Cellini Claudia,Gobbi Marco,Ballanti Stelvio,de Fabritiis Paolo,Mosca-Siez Maria Letizia,Marchetti Monia,Liberati Anna Marina,Offidani Massimo,Giuliani Nicola,Ria Roberto^ORCID,Musto Pellegrino,Romano Alessandra,Sonneveld Pieter,Boccadoro Mario,Larocca Alessandra^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://www.nature.com/articles/s41408-020-0326-1.pdf

Reference15 articles.

1. McCarthy, P. L. et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin.Oncol. 35, 3279–3289 (2017).

2. Dimopoulos, M. A. et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet 393, 253–264 (2019).

3. Sonneveld, P. et al. Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial. J. Clin. Oncol. 30, 2946–2955 (2012).

4. Richardson, P. G. et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352, 2487–98. (2005).

5. Palumbo, A. et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N. Engl. J. Med. 375, 754–766 (2016).

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A rational approach to functional high-risk myeloma;Hematology;2023-12-08

2. Detection of Measurable Residual Disease Biomarkers in Extracellular Vesicles from Liquid Biopsies of Multiple Myeloma Patients—A Proof of Concept;International Journal of Molecular Sciences;2022-11-08

3. Optimal timing of treatment at relapse after autologous stem cell transplantation in patients with multiple myeloma: a study of the Korean Multiple Myeloma Working Party (KMM-1909);Bone Marrow Transplantation;2022-09-22

4. Immunophenotypic Characteristics of Bone Marrow Microenvironment Cellular Composition at the Biochemical Progression of Multiple Myeloma;Journal of Clinical Medicine;2022-06-27

5. Measurable Residual Disease Assessment in Multiple Myeloma: How Deep Is Enough?;Hemato;2022-06-23